Revision of USP <1099> Limit on Number of Large Deviations When Assessing Content Uniformity in Large Samples
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In the Pharmacopeial Forum, PF 47(4), a proposal of USP Chapter <1099> Limit on Number of Large Deviations When Assessing Content Uniformity in Large Samples has been published for comments.
The proposal is based on the version of the monograph official as of March 1, 2019, but the chapter was completely revised.
According to the USP, the new chapter "is presented with a general approach that provides a process for evaluating the number of observed results that fall outside defined limits. The approach can also be used for tests that are inherently pass/fail in nature. It should be noted that the procedure described in this chapter is not intended as a batch release test for content uniformity nor as a replacement of or alternative to Uniformity of Dosage Units <905> for compendial purposes."Comments on the chapter can be submitted from now on. The comment deadline is September 30, 2021.
The draft can be viewed here. (Please note: a one-time registration is required to access the Pharmacopeial Forum.)
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


